"The formulary started as a
clinical tool, but for most PBMs it has really become a vehicle for market
share manipulation. While it may deliver some financial value to PBM clients,
it is not really a 'value-based' approach."
— Josh Golden, area senior vice
president at Solid Benefit Guidance (a division of Arthur J. Gallagher &
Co.), tells Drug Benefit News he "takes issue"
with some PBMs expanding the definition of value-based pricing to include
formulary exclusions.
No comments:
Post a Comment